Clinical Trial Update: Oral Naltrexone In Pediatric Eating Disorders [Phase 2, Phase 3]

View source ↗

Summary

A pediatric trial evaluating oral naltrexone for eating disorders (Phase 2/3) was terminated, with results posted on 2025-08-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anorexia Nervosa
• Bulimia Nervosa
• Eating Disorders

Drugs mentioned

• Naltrexone (Naltrexone)

Snippet

Sponsor: Rosemary Claire Roden | Conditions: Anorexia Nervosa/Bulimia, Anorexia in Adolescence | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-08-19